D. Scott McMeekin

7.6k citations

121 papers · 5.6k indexed · 3 hit papers · h-index 40

Co-authors: Michael W. Sill Paul DiSilvestro J Bénda David E. Cohn Joan L. Walker Robert S. Mannel Kathleen N. Moore Michael A. Gold
Topics: Endometrial and Cervical Cancer Treatments (73 papers)Ovarian cancer diagnosis and treatment (69 papers)Endometriosis Research and Treatment (19 papers)
Cited by: Obstetrics and Gynecology Reproductive Medicine Oncology
Journals: Journal of Clinical Oncology JNCI Journal of the National Cancer Institute Cancer
Partner nations: United States United Kingdom Canada

In The Last Decade

D. Scott McMeekin

117 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

2008 641 citations Richard G. Moore, D. Scott McMeekin et al. Gynecologic Oncology profile →
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

2009 497 citations Bradley J. Monk, Michael W. Sill et al. Journal of Clinical Oncology profile →
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer

2019 209 citations Marcus E. Randall, Virginia L. Filiaci et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by D. Scott McMeekin

Since Specialization

Citations

This map shows the geographic impact of D. Scott McMeekin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Scott McMeekin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Scott McMeekin more than expected).

Fields of papers citing papers by D. Scott McMeekin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Scott McMeekin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Scott McMeekin. The network helps show where D. Scott McMeekin may publish in the future.

Co-authorship network of co-authors of D. Scott McMeekin

This figure shows the co-authorship network connecting the top 25 collaborators of D. Scott McMeekin. A scholar is included among the top collaborators of D. Scott McMeekin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Scott McMeekin. D. Scott McMeekin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancerbreakdown → 2019 ·Journal of Clinical Oncology ·Marcus E. Randall,Virginia L. Filiaci,D. Scott McMeekin,Vivian von Gruenigen,Helen Huang,Catheryn M. Yashar,Robert S. Mannel,Jae‐Weon Kim,Ritu Salani,Paul DiSilvestro,James J. Burke,Thomas Rutherford,Nick M. Spirtos,Keith Y. Terada,Penny R. Anderson,Wendy R. Brewster,William Small,Carol Aghajanian,David S. Miller	209
2	The pro-inflammatory effect of obesity on high grade serous ovarian cancer 2016 ·Gynecologic Oncology ·Camille C. Gunderson,Kai Ding,Justin Dvorak,Kathleen N. Moore,D. Scott McMeekin,Doris M. Benbrook	6
3	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial 2015 ·Obstetrical & Gynecological Survey ·Ashley S. Felix,Louise A. Brinton,D. Scott McMeekin,William T. Creasman,David G. Mutch,David E. Cohn,Joan L. Walker,Richard G. Moore,Levi S. Downs,Robert A. Soslow,Richard J. Zaino,Mark E. Sherman	2
4	A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies 2015 ·Cancer Chemotherapy and Pharmacology ·Stephen K. Williamson,Gary A. Johnson,(unknown),Kathleen N. Moore,D. Scott McMeekin,Thomas K. Schulz,Gregory A. Reed,Katherine F. Roby,(unknown),H. John Smith,Scott J. Weir,Jo Wick,Maurie Markman,Gere S. diZerega,(unknown),(unknown),Charles J. Decedue	52
5	Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors 2013 ·Gynecologic Oncology ·Lisa M. Landrum,Elizabeth Nugent,Rosemary E. Zuna,(unknown),Robert S. Mannel,Kathleen N. Moore,Joan L. Walker,D. Scott McMeekin	29
6	Distance Traveled for Treatment of Cervical Cancer 2013 ·International Journal of Gynecological Cancer ·Camille C. Gunderson,Elizabeth Nugent,D. Scott McMeekin,Kathleen N. Moore	31
7	Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies 2012 ·Cancer Prevention Research ·Summer Dewdney,Nora T. Kizer,Abegail A. Andaya,(unknown),Jingqin Luo,David G. Mutch,Amy P. Schmidt,Louise A. Brinton,Russell R. Broaddus,Nilsa C. Ramirez,Phyllis C. Huettner,D. Scott McMeekin,Kathleen M. Darcy,Shamshad Ali,Patricia L. Judson,Robert S. Mannel,Shashikant B. Lele,David M. O’Malley,Paul J. Goodfellow	17
8	Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study 2011 ·Journal of Clinical Oncology ·Carol Aghajanian,Michael W. Sill,Kathleen M. Darcy,Benjamin E. Greer,D. Scott McMeekin,Peter G. Rose,Jacob Rotmensch,Mack N. Barnes,Parviz Hanjani,Kimberly K. Leslie	214
9	A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study 2011 ·Gynecologic Oncology ·Robert L. Coleman,William E. Brady,D. Scott McMeekin,Peter G. Rose,John T. Soper,Samuel S. Lentz,James Hoffman,Mark S. Shahin	88
10	Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study 2011 ·Gynecologic Oncology ·Alessandro D. Santin,Michael W. Sill,D. Scott McMeekin,Mario M. Leitão,Jubilee Brown,Gregory P. Sutton,Linda Van Le,Patricia Griffin,Cecelia H. Boardman	82
11	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study 2010 ·Gynecologic Oncology ·David Cella,Helen Huang,Bradley J. Monk,Lari Wenzel,J Bénda,D. Scott McMeekin,David E. Cohn,Lois M. Ramondetta,Cecelia H. Boardman	27
12	Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study 2009 ·Gynecologic Oncology ·Gini F. Fleming,Michael W. Sill,Kathleen M. Darcy,D. Scott McMeekin,J.T. Thigpen,Lisa Adler,Jonathan S. Berek,Julia Chapman,Paul DiSilvestro,Ira Horowitz,James V. Fiorica	200
13	Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study 2009 ·Gynecologic Oncology ·D. Scott McMeekin,Alla Lisyanskaya,Marta A. Crispens,Amit M. Oza,Patricia S. Braly,David L. Doering,Eliel Bayever,B. Michiels,Maurie Markman	16
14	Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study 2008 ·Gynecologic Oncology ·D. Scott McMeekin,Joan L. Walker,Ellen M. Hartenbach,Michael A. Bookman,Wui-Jin Koh	6
15	A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens 2007 ·British Journal of Cancer ·(unknown),Carolyn Krasner,D. Scott McMeekin,Stephen Chan,Patricia S. Braly,(unknown),Stan B. Kaye,Diane Provencher,(unknown),Martin Gore	85
16	The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study 2007 ·Gynecologic Oncology ·D. Scott McMeekin,Virginia L. Filiaci,J.T. Thigpen,Holly H. Gallion,Gini F. Fleming,William H. Rodgers	110
17	Preoperative predictors of positive margins after loop electrosurgical excisional procedure–Cone 2005 ·Gynecologic Oncology ·Todd Tillmanns,(unknown),(unknown),Jim Y. Wan,Robert S. Mannel,Joan L. Walker,Gary A. Johnson,D. Scott McMeekin,(unknown),Michael A. Gold	21
18	Surgical–pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? 2004 ·Gynecologic Oncology ·Scott Kamelle,Teresa Rutledge,Todd Tillmanns,(unknown),David E. Cohn,Jason D. Wright,Thomas J. Herzog,Janet S. Rader,Michael A. Gold,Gary A. Johnson,Joan L. Walker,Robert S. Mannel,D. Scott McMeekin	26
19	A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer 2003 ·Gynecologic Oncology ·D. Scott McMeekin,Alan N. Gordon,Jeffrey M. Fowler,Allen S. Melemed,Richard E. Buller,Thomas J. Burke,J. Bloss,Paul Sabbatini	55
20	Laparoscopic Pelvic and Paraaortic Lymph Node Dissection in the Obese 2002 ·Gynecologic Oncology ·Dennis R. Scribner,Joan L. Walker,Gary A. Johnson,D. Scott McMeekin,Michael A. Gold,Robert S. Mannel	87

About D. Scott McMeekin

D. Scott McMeekin is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology, having authored 121 papers that have together received 5.6k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (73 papers), Ovarian cancer diagnosis and treatment (69 papers) and Endometriosis Research and Treatment (19 papers). The work is most often cited by research in Obstetrics and Gynecology (3.3k citations), Reproductive Medicine (2.8k citations) and Oncology (1.3k citations). D. Scott McMeekin has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Michael W. Sill, Paul DiSilvestro, J Bénda, David E. Cohn, Joan L. Walker, Robert S. Mannel, Kathleen N. Moore, Michael A. Gold, Richard G. Moore and Bradley J. Monk. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact